{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T17:37:42Z","timestamp":1794850662081,"version":"4.9.1"},"reference-count":148,"publisher":"Springer Science and Business Media LLC","issue":"S2","license":[{"start":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T00:00:00Z","timestamp":1712620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T00:00:00Z","timestamp":1712620800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370577"],"award-info":[{"award-number":["82370577"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82070588"],"award-info":[{"award-number":["82070588"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82000690"],"award-info":[{"award-number":["82000690"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2023M732681"],"award-info":[{"award-number":["2023M732681"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s12072-024-10660-y","type":"journal-article","created":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T13:01:40Z","timestamp":1712667700000},"page":"834-847","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":66,"title":["MAFLD as part of systemic metabolic dysregulation"],"prefix":"10.1007","volume":"18","author":[{"given":"Jing","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Ying","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Targher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher D.","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan-Qin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4984-2631","authenticated-orcid":false,"given":"Ming-Hua","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,9]]},"reference":[{"key":"10660_CR1","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/s41575-023-00846-4","volume":"21","author":"G Feng","year":"2024","unstructured":"Feng G, Valenti L, Wong VW, Fouad YM, Yilmaz Y, Kim W, et al. Recompensation in cirrhosis: unravelling the evolving natural history of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2024;21:46\u201356","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10660_CR2","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.jhep.2023.04.036","volume":"79","author":"VW Wong","year":"2023","unstructured":"Wong VW, Ekstedt M, Wong GL, Hagstr\u00f6m H. Changing epidemiology, global trends and implications for outcomes of NAFLD. J Hepatol. 2023;79:842\u2013852","journal-title":"J Hepatol"},{"key":"10660_CR3","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1146\/annurev-med-042220-020407","volume":"73","author":"Y Saiman","year":"2022","unstructured":"Saiman Y, Duarte-Rojo A, Rinella ME. Fatty liver disease: diagnosis and stratification. Annu Rev Med. 2022;73:529\u2013544","journal-title":"Annu Rev Med"},{"key":"10660_CR4","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/S2468-1253(22)00062-0","volume":"7","author":"N Mendez-Sanchez","year":"2022","unstructured":"Mendez-Sanchez N, Bugianesi E, Gish RG, Lammert F, Tilg H, Nguyen MH, et al. Global multi-stakeholder endorsement of the MAFLD definition. Lancet Gastroenterol Hepatol. 2022;7:388\u2013390","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10660_CR5","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73:202\u2013209","journal-title":"J Hepatol"},{"key":"10660_CR6","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.jhep.2020.12.016","volume":"74","author":"KI Zheng","year":"2021","unstructured":"Zheng KI, Sun DQ, Jin Y, Zhu PW, Zheng MH. Clinical utility of the MAFLD definition. J Hepatol. 2021;74:989\u2013991","journal-title":"J Hepatol"},{"key":"10660_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/emm.2015.122","volume":"48","author":"HS Han","year":"2016","unstructured":"Han HS, Kang G, Kim JS, Choi BH, Koo SH. Regulation of glucose metabolism from a liver-centric perspective. Exp Mol Med. 2016;48: e218","journal-title":"Exp Mol Med"},{"key":"10660_CR8","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1038\/s42255-021-00501-9","volume":"3","author":"H Tilg","year":"2021","unstructured":"Tilg H, Adolph TE, Dudek M, Knolle P. Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity. Nat Metab. 2021;3:1596\u20131607","journal-title":"Nat Metab"},{"key":"10660_CR9","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","volume":"62","author":"CD Byrne","year":"2015","unstructured":"Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62:S47-64","journal-title":"J Hepatol"},{"key":"10660_CR10","doi-asserted-by":"publisher","first-page":"204201882211455","DOI":"10.1177\/20420188221145549","volume":"14","author":"RM Pipitone","year":"2023","unstructured":"Pipitone RM, Ciccioli C, Infantino G, La Mantia C, Parisi S, Tulone A, et al. MAFLD: a multisystem disease. Ther Adv Endocrinol Metab. 2023;14:20420188221145548","journal-title":"Ther Adv Endocrinol Metab"},{"key":"10660_CR11","doi-asserted-by":"publisher","first-page":"329","DOI":"10.14218\/JCTH.2021.00178","volume":"10","author":"E Kaya","year":"2022","unstructured":"Kaya E, Yilmaz Y. Metabolic-associated fatty liver disease (MAFLD): a multi-systemic disease beyond the liver. J Clin Transl Hepatol. 2022;10:329\u2013338","journal-title":"J Clin Transl Hepatol"},{"key":"10660_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2020.154433","volume":"115","author":"DQ Sun","year":"2021","unstructured":"Sun DQ, Jin Y, Wang TY, Zheng KI, Rios RS, Zhang HY, et al. MAFLD and risk of CKD. Metabolism. 2021;115: 154433","journal-title":"Metabolism"},{"key":"10660_CR13","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/s41581-021-00519-y","volume":"18","author":"TY Wang","year":"2022","unstructured":"Wang TY, Wang RF, Bu ZY, Targher G, Byrne CD, Sun DQ, et al. Association of metabolic dysfunction-associated fatty liver disease with kidney disease. Nat Rev Nephrol. 2022;18:259\u2013268","journal-title":"Nat Rev Nephrol"},{"key":"10660_CR14","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1186\/s12933-022-01697-0","volume":"21","author":"XD Zhou","year":"2022","unstructured":"Zhou XD, Cai J, Targher G, Byrne CD, Shapiro MD, Sung KC, et al. Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention. Cardiovasc Diabetol. 2022;21:270","journal-title":"Cardiovasc Diabetol"},{"key":"10660_CR15","doi-asserted-by":"publisher","first-page":"3920196","DOI":"10.1155\/2020\/3920196","volume":"2020","author":"DM Tanase","year":"2020","unstructured":"Tanase DM, Gosav EM, Costea CF, Ciocoiu M, Lacatusu CM, Maranduca MA, et al. The intricate relationship between type 2 diabetes mellitus (T2DM), insulin resistance (IR), and nonalcoholic fatty liver disease (NAFLD). J Diabetes Res. 2020;2020:3920196","journal-title":"J Diabetes Res"},{"key":"10660_CR16","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1097\/MCG.0000000000000666","volume":"51","author":"R Jinjuvadia","year":"2017","unstructured":"Jinjuvadia R, Antaki F, Lohia P, Liangpunsakul S. The association between nonalcoholic fatty liver disease and metabolic abnormalities in the United States population. J Clin Gastroenterol. 2017;51:160\u2013166","journal-title":"J Clin Gastroenterol"},{"key":"10660_CR17","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1002\/hep.28985","volume":"65","author":"F Bril","year":"2017","unstructured":"Bril F, Barb D, Portillo-Sanchez P, Biernacki D, Lomonaco R, Suman A, et al. Metabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver disease. Hepatology. 2017;65:1132\u20131144","journal-title":"Hepatology"},{"key":"10660_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-013781","volume":"6","author":"DQ Sun","year":"2016","unstructured":"Sun DQ, Wu SJ, Liu WY, Wang LR, Chen YR, Zhang DC, et al. Association of low-density lipoprotein cholesterol within the normal range and NAFLD in the non-obese Chinese population: a cross-sectional and longitudinal study. BMJ Open. 2016;6: e013781","journal-title":"BMJ Open"},{"key":"10660_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2021.101349","volume":"54","author":"A Heida","year":"2021","unstructured":"Heida A, Gruben N, Catrysse L, Koehorst M, Koster M, Kloosterhuis NJ, et al. The hepatocyte IKK:NF-\u03baB axis promotes liver steatosis by stimulating de novo lipogenesis and cholesterol synthesis. Mol Metab. 2021;54: 101349","journal-title":"Mol Metab"},{"key":"10660_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2023.100845","volume":"5","author":"A Hammoutene","year":"2023","unstructured":"Hammoutene A, Laouirem S, Albuquerque M, Colnot N, Brzustowski A, Valla D, et al. A new NRF2 activator for the treatment of human metabolic dysfunction-associated fatty liver disease. JHEP Rep. 2023;5: 100845","journal-title":"JHEP Rep"},{"key":"10660_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2021.154725","volume":"117","author":"F Teng","year":"2021","unstructured":"Teng F, Jiang J, Zhang J, Yuan Y, Li K, Zhou B, et al. The S100 calcium-binding protein A11 promotes hepatic steatosis through RAGE-mediated AKT-mTOR signaling. Metabolism. 2021;117: 154725","journal-title":"Metabolism"},{"key":"10660_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2022.154219","volume":"103","author":"Y Gu","year":"2022","unstructured":"Gu Y, Duan S, Ding M, Zheng Q, Fan G, Li X, et al. Saikosaponin D attenuates metabolic associated fatty liver disease by coordinately tuning PPAR\u03b1 and INSIG\/SREBP1c pathway. Phytomedicine. 2022;103: 154219","journal-title":"Phytomedicine"},{"key":"10660_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.680081","volume":"12","author":"B Yang","year":"2021","unstructured":"Yang B, Sun J, Liang S, Wu P, Lv R, He Y, et al. Prediction of Srebp-1 as a key target of Qing Gan San against MAFLD in rats via RNA-sequencing profile analysis. Front Pharmacol. 2021;12: 680081","journal-title":"Front Pharmacol"},{"key":"10660_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202200742","volume":"9","author":"H Lin","year":"2022","unstructured":"Lin H, Wang L, Liu Z, Long K, Kong M, Ye D, et al. Hepatic MDM2 causes metabolic associated fatty liver disease by blocking triglyceride-VLDL secretion via ApoB degradation. Adv Sci (Weinh). 2022;9: e2200742","journal-title":"Adv Sci (Weinh)"},{"key":"10660_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2022.120838","volume":"306","author":"Z Junli","year":"2022","unstructured":"Junli Z, Shuhan W, Yajuan Z, Xiaoling D, Jiahuan L, Keshu X. The role and mechanism of CREBH regulating SIRT3 in metabolic associated fatty liver disease. Life Sci. 2022;306: 120838","journal-title":"Life Sci"},{"key":"10660_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111344","volume":"137","author":"C Ma","year":"2021","unstructured":"Ma C, Wang Z, Xia R, Wei L, Zhang C, Zhang J, et al. Danthron ameliorates obesity and MAFLD through activating the interplay between PPAR\u03b1\/RXR\u03b1 heterodimer and adiponectin receptor 2. Biomed Pharmacother. 2021;137: 111344","journal-title":"Biomed Pharmacother"},{"key":"10660_CR27","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202201950R","volume":"37","author":"J Wang","year":"2023","unstructured":"Wang J, Zhang F, Yang W, Gao D, Yang L, Yu C, et al. FGF1 ameliorates obesity-associated hepatic steatosis by reversing IGFBP2 hypermethylation. Faseb J. 2023;37: e22881","journal-title":"Faseb J"},{"key":"10660_CR28","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1016\/j.clnu.2022.08.001","volume":"41","author":"C Boutari","year":"2022","unstructured":"Boutari C, Pappas PD, Anastasilakis D, Mantzoros CS. Statins\u2019 efficacy in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Clin Nutr. 2022;41:2195\u20132206","journal-title":"Clin Nutr"},{"key":"10660_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104392","volume":"87","author":"I Ayada","year":"2023","unstructured":"Ayada I, van Kleef LA, Zhang H, Liu K, Li P, Abozaid YJ, et al. Dissecting the multifaceted impact of statin use on fatty liver disease: a multidimensional study. EBioMedicine. 2023;87: 104392","journal-title":"EBioMedicine"},{"key":"10660_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2023.176159","volume":"960","author":"D Zhang","year":"2023","unstructured":"Zhang D, Ma Y, Liu J, Wang D, Geng Z, Wen D, et al. Fenofibrate improves hepatic steatosis, insulin resistance, and shapes the gut microbiome via TFEB-autophagy in NAFLD mice. Eur J Pharmacol. 2023;960: 176159","journal-title":"Eur J Pharmacol"},{"key":"10660_CR31","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.cgh.2021.12.044","volume":"21","author":"EJ Lawitz","year":"2023","unstructured":"Lawitz EJ, Bhandari BR, Ruane PJ, Kohli A, Harting E, Ding D, et al. Fenofibrate mitigates hypertriglyceridemia in nonalcoholic steatohepatitis patients treated with cilofexor\/firsocostat. Clin Gastroenterol Hepatol. 2023;21:143-152.e143","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10660_CR32","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.tem.2022.03.005","volume":"33","author":"JS Moon","year":"2022","unstructured":"Moon JS, Hong JH, Jung YJ, Ferrannini E, Nauck MA, Lim S. SGLT-2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver disease. Trends Endocrinol Metab. 2022;33:424\u2013442","journal-title":"Trends Endocrinol Metab"},{"key":"10660_CR33","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/S2468-1253(21)00261-2","volume":"7","author":"A Mantovani","year":"2022","unstructured":"Mantovani A, Byrne CD, Targher G. Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review. Lancet Gastroenterol Hepatol. 2022;7:367\u2013378","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10660_CR34","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1210\/clinem\/dgab641","volume":"107","author":"Y Liang","year":"2022","unstructured":"Liang Y, Chen H, Liu Y, Hou X, Wei L, Bao Y, et al. Association of MAFLD with diabetes, chronic kidney disease, and cardiovascular disease: a 46-year cohort study in China. J Clin Endocrinol Metab. 2022;107:88\u201397","journal-title":"J Clin Endocrinol Metab"},{"key":"10660_CR35","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1136\/gutjnl-2020-322572","volume":"70","author":"A Mantovani","year":"2021","unstructured":"Mantovani A, Petracca G, Beatrice G, Tilg H, Byrne CD, Targher G. Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501,022 adult individuals. Gut. 2021;70:962\u2013969","journal-title":"Gut"},{"key":"10660_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2023.154740","volume":"114","author":"X Fan","year":"2023","unstructured":"Fan X, Jiao G, Pang T, Wen T, He Z, Han J, et al. Ameliorative effects of mangiferin derivative TPX on insulin resistance via PI3K\/AKT and AMPK signaling pathways in human HepG2 and HL-7702 hepatocytes. Phytomedicine. 2023;114: 154740","journal-title":"Phytomedicine"},{"key":"10660_CR37","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s13578-023-01119-y","volume":"13","author":"T Liu","year":"2023","unstructured":"Liu T, Li R, Sun L, Xu Z, Wang S, Zhou J, et al. Menin orchestrates hepatic glucose and fatty acid uptake via deploying the cellular translocation of SIRT1 and PPAR\u03b3. Cell Biosci. 2023;13:175","journal-title":"Cell Biosci"},{"key":"10660_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2023.101779","volume":"76","author":"M Karpale","year":"2023","unstructured":"Karpale M, Kummu O, K\u00e4rkk\u00e4inen O, Lehtonen M, N\u00e4p\u00e4nkangas J, Herfurth UM, et al. Pregnane X receptor activation remodels glucose metabolism to promote NAFLD development in obese mice. Mol Metab. 2023;76: 101779","journal-title":"Mol Metab"},{"key":"10660_CR39","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/hepr.13888","volume":"53","author":"Y Fan","year":"2023","unstructured":"Fan Y, Zhang Y, Chen C, Ying Z, Su Q, Li X, et al. Fasting serum fructose is associated with metabolic dysfunction-associated fatty liver disease: a prospective study. Hepatol Res. 2023;53:479\u2013488","journal-title":"Hepatol Res"},{"key":"10660_CR40","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1152\/physrev.00010.2008","volume":"89","author":"P Lefebvre","year":"2009","unstructured":"Lefebvre P, Cariou B, Lien F, Kuipers F, Staels B. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev. 2009;89:147\u2013191","journal-title":"Physiol Rev"},{"key":"10660_CR41","doi-asserted-by":"publisher","first-page":"4s","DOI":"10.1002\/hep.1840040803","volume":"4","author":"AF Hofmann","year":"1984","unstructured":"Hofmann AF. Chemistry and enterohepatic circulation of bile acids. Hepatology. 1984;4:4s\u201314s","journal-title":"Hepatology"},{"key":"10660_CR42","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1111\/apt.17362","volume":"57","author":"AN Liu","year":"2023","unstructured":"Liu AN, Xu CF, Liu YR, Sun DQ, Jiang L, Tang LJ, et al. Secondary bile acids improve risk prediction for non-invasive identification of mild liver fibrosis in nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2023;57:872\u2013885","journal-title":"Aliment Pharmacol Ther"},{"key":"10660_CR43","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1111\/1751-7915.14293","volume":"16","author":"W Wu","year":"2023","unstructured":"Wu W, Kaicen W, Bian X, Yang L, Ding S, Li Y, et al. Akkermansia muciniphila alleviates high-fat-diet-related metabolic-associated fatty liver disease by modulating gut microbiota and bile acids. Microb Biotechnol. 2023;16:1924\u20131939","journal-title":"Microb Biotechnol"},{"key":"10660_CR44","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1016\/j.cmet.2021.04.009","volume":"33","author":"A Castellanos-Jankiewicz","year":"2021","unstructured":"Castellanos-Jankiewicz A, Guzm\u00e1n-Quevedo O, F\u00e9nelon VS, Zizzari P, Quarta C, Bellocchio L, et al. Hypothalamic bile acid-TGR5 signaling protects from obesity. Cell Metab. 2021;33:1483-1492.e1410","journal-title":"Cell Metab"},{"key":"10660_CR45","doi-asserted-by":"publisher","first-page":"1007274","DOI":"10.3389\/fphar.2022.1007274","volume":"13","author":"J He","year":"2022","unstructured":"He J, Yang Y, Zhang F, Li Y, Li X, Pu X, et al. Effects of Poria cocos extract on metabolic dysfunction-associated fatty liver disease via the FXR\/PPAR\u03b1-SREBPs pathway. Front Pharmacol. 2022;13:1007274","journal-title":"Front Pharmacol"},{"key":"10660_CR46","doi-asserted-by":"publisher","first-page":"2707","DOI":"10.3390\/nu14132707","volume":"14","author":"J Gillard","year":"2022","unstructured":"Gillard J, Picalausa C, Ullmer C, Adorini L, Staels B, Tailleux A, et al. Enterohepatic takeda g-protein coupled receptor 5 agonism in metabolic dysfunction-associated fatty liver disease and related glucose dysmetabolism. Nutrients. 2022;14:2707","journal-title":"Nutrients"},{"key":"10660_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2023.101841","volume":"79","author":"DQ Sun","year":"2023","unstructured":"Sun DQ, Yuan F, Fu MZ, Zhong MY, Zhang SL, Lu Y, et al. Farnesoid X receptor activation protects against renal fibrosis via modulation of \u03b2-catenin signaling. Mol Metab. 2023;79: 101841","journal-title":"Mol Metab"},{"key":"10660_CR48","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.1111\/liv.15455","volume":"42","author":"H He","year":"2022","unstructured":"He H, Liao S, Zeng Y, Liang L, Chen J, Tao C. Causal relationships between metabolic-associated fatty liver disease and iron status: Two-sample Mendelian randomization. Liver Int. 2022;42:2759\u20132768","journal-title":"Liver Int"},{"key":"10660_CR49","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1111\/liv.15163","volume":"42","author":"G Feng","year":"2022","unstructured":"Feng G, Byrne CD, Targher G, Wang F, Zheng MH. Ferroptosis and metabolic dysfunction-associated fatty liver disease: is there a link? Liver Int. 2022;42:1496\u20131502","journal-title":"Liver Int"},{"key":"10660_CR50","doi-asserted-by":"publisher","first-page":"3650","DOI":"10.1016\/j.apsb.2022.02.003","volume":"12","author":"J Tong","year":"2022","unstructured":"Tong J, Li D, Meng H, Sun D, Lan X, Ni M, et al. Targeting a novel inducible GPX4 alternative isoform to alleviate ferroptosis and treat metabolic-associated fatty liver disease. Acta Pharm Sin B. 2022;12:3650\u20133666","journal-title":"Acta Pharm Sin B"},{"key":"10660_CR51","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1038\/s41401-022-01010-5","volume":"44","author":"J Tong","year":"2023","unstructured":"Tong J, Lan XT, Zhang Z, Liu Y, Sun DY, Wang XJ, et al. Ferroptosis inhibitor liproxstatin-1 alleviates metabolic dysfunction-associated fatty liver disease in mice: potential involvement of PANoptosis. Acta Pharmacol Sin. 2023;44:1014\u20131028","journal-title":"Acta Pharmacol Sin"},{"key":"10660_CR52","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/s41580-020-00324-8","volume":"22","author":"X Jiang","year":"2021","unstructured":"Jiang X, Stockwell BR, Conrad M. Ferroptosis: mechanisms, biology and role in disease. Nat Rev Mol Cell Biol. 2021;22:266\u2013282","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10660_CR53","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.freeradbiomed.2022.10.270","volume":"193","author":"S Liu","year":"2022","unstructured":"Liu S, Gao Z, He W, Wu Y, Liu J, Zhang S, et al. The gut microbiota metabolite glycochenodeoxycholate activates TFR-ACSL4-mediated ferroptosis to promote the development of environmental toxin-linked MAFLD. Free Radic Biol Med. 2022;193:213\u2013226","journal-title":"Free Radic Biol Med"},{"key":"10660_CR54","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41572-018-0018-3","volume":"4","author":"A Cz\u0142onkowska","year":"2018","unstructured":"Cz\u0142onkowska A, Litwin T, Dusek P, Ferenci P, Lutsenko S, Medici V, et al. Wilson disease. Nat Rev Dis Primers. 2018;4:21","journal-title":"Nat Rev Dis Primers"},{"key":"10660_CR55","doi-asserted-by":"publisher","first-page":"441","DOI":"10.3109\/10715769809066881","volume":"28","author":"M Koizumi","year":"1998","unstructured":"Koizumi M, Fujii J, Suzuki K, Inoue T, Inoue T, Gutteridge JM, et al. A marked increase in free copper levels in the plasma and liver of LEC rats: an animal model for Wilson disease and liver cancer. Free Radic Res. 1998;28:441\u2013450","journal-title":"Free Radic Res"},{"key":"10660_CR56","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1016\/j.clnu.2020.09.026","volume":"40","author":"Y Lan","year":"2021","unstructured":"Lan Y, Wu S, Wang Y, Chen S, Liao W, Zhang X, et al. Association between blood copper and nonalcoholic fatty liver disease according to sex. Clin Nutr. 2021;40:2045\u20132052","journal-title":"Clin Nutr"},{"key":"10660_CR57","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jtemb.2018.06.001","volume":"50","author":"SH Lee","year":"2018","unstructured":"Lee SH, Kim MJ, Kim YS, Chun H, Won BY, Lee JH, et al. Low hair copper concentration is related to a high risk of nonalcoholic fatty liver disease in adults. J Trace Elem Med Biol. 2018;50:28\u201333","journal-title":"J Trace Elem Med Biol"},{"key":"10660_CR58","doi-asserted-by":"publisher","first-page":"7280","DOI":"10.3390\/ijms23137280","volume":"23","author":"R Ramanathan","year":"2022","unstructured":"Ramanathan R, Ali AH, Ibdah JA. Mitochondrial dysfunction plays central role in nonalcoholic fatty liver disease. Int J Mol Sci. 2022;23:7280","journal-title":"Int J Mol Sci"},{"key":"10660_CR59","doi-asserted-by":"publisher","first-page":"6873","DOI":"10.3390\/ijms23126873","volume":"23","author":"P Fahlbusch","year":"2022","unstructured":"Fahlbusch P, Nikolic A, Hartwig S, Jacob S, Kettel U, K\u00f6llmer C, et al. Adaptation of oxidative phosphorylation machinery compensates for hepatic lipotoxicity in early stages of MAFLD. Int J Mol Sci. 2022;23:6873","journal-title":"Int J Mol Sci"},{"key":"10660_CR60","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3390\/genes13020315","volume":"13","author":"F Cioffi","year":"2022","unstructured":"Cioffi F, Giacco A, Petito G, de Matteis R, Senese R, Lombardi A, et al. Altered mitochondrial quality control in rats with metabolic dysfunction-associated fatty liver disease (MAFLD) induced by high-fat feeding. Genes (Basel). 2022;13:315","journal-title":"Genes (Basel)"},{"key":"10660_CR61","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241210360","volume":"24","author":"J San","year":"2023","unstructured":"San J, Hu J, Pang H, Zuo W, Su N, Guo Z, et al. Taurine protects against the fatty liver hemorrhagic syndrome in laying hens through the regulation of mitochondrial homeostasis. Int J Mol Sci. 2023;24: 10360","journal-title":"Int J Mol Sci"},{"key":"10660_CR62","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.895593","volume":"13","author":"Y Ma","year":"2022","unstructured":"Ma Y, Chen G, Yi J, Li Q, Tan Z, Fan W, et al. IRX3 plays an important role in the pathogenesis of metabolic-associated fatty liver disease by regulating hepatic lipid metabolism. Front Endocrinol (Lausanne). 2022;13: 895593","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10660_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2022.102277","volume":"51","author":"V Scalcon","year":"2022","unstructured":"Scalcon V, Folda A, Lupo MG, Tonolo F, Pei N, Battisti I, et al. Mitochondrial depletion of glutaredoxin 2 induces metabolic dysfunction-associated fatty liver disease in mice. Redox Biol. 2022;51: 102277","journal-title":"Redox Biol"},{"key":"10660_CR64","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41575-018-0082-x","volume":"16","author":"K Kazankov","year":"2019","unstructured":"Kazankov K, J\u00f8rgensen SMD, Thomsen KL, M\u00f8ller HJ, Vilstrup H, George J, et al. The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Nat Rev Gastroenterol Hepatol. 2019;16:145\u2013159","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10660_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2022.175468","volume":"940","author":"B Lu","year":"2023","unstructured":"Lu B, Wang D, Xie D, Wu C, Sun M. 20(S)-Protopanaxatriol ameliorates MAFLD by inhibiting NLRP3 inflammasome. Eur J Pharmacol. 2023;940: 175468","journal-title":"Eur J Pharmacol"},{"key":"10660_CR66","doi-asserted-by":"publisher","first-page":"7430","DOI":"10.1038\/s41467-022-35158-9","volume":"13","author":"J Alharthi","year":"2022","unstructured":"Alharthi J, Bayoumi A, Thabet K, Pan Z, Gloss BS, Latchoumanin O, et al. A metabolic associated fatty liver disease risk variant in MBOAT7 regulates toll like receptor induced outcomes. Nat Commun. 2022;13:7430","journal-title":"Nat Commun"},{"key":"10660_CR67","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.immuni.2020.08.004","volume":"53","author":"A Remmerie","year":"2020","unstructured":"Remmerie A, Martens L, Thon\u00e9 T, Castoldi A, Seurinck R, Pavie B, et al. Osteopontin expression identifies a subset of recruited macrophages distinct from Kupffer cells in the fatty liver. Immunity. 2020;53:641-657.e614","journal-title":"Immunity"},{"key":"10660_CR68","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1080\/14728222.2022.2132145","volume":"26","author":"TL Laursen","year":"2022","unstructured":"Laursen TL, Mellemkj\u00e6r A, M\u00f8ller HJ, Gr\u00f8nb\u00e6k H, Kazankov K. Spotlight on liver macrophages for halting injury and progression in nonalcoholic fatty liver disease. Expert Opin Ther Targets. 2022;26:697\u2013705","journal-title":"Expert Opin Ther Targets"},{"key":"10660_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2021.112801","volume":"407","author":"L Li","year":"2021","unstructured":"Li L, Xia Y, Ji X, Wang H, Zhang Z, Lu P, et al. MIG\/CXCL9 exacerbates the progression of metabolic-associated fatty liver disease by disrupting Treg\/Th17 balance. Exp Cell Res. 2021;407: 112801","journal-title":"Exp Cell Res"},{"key":"10660_CR70","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.add1599","volume":"8","author":"S Marinovi\u0107","year":"2023","unstructured":"Marinovi\u0107 S, Lenarti\u0107 M, Mladeni\u0107 K, \u0160estan M, Kavazovi\u0107 I, Beni\u0107 A, et al. NKG2D-mediated detection of metabolically stressed hepatocytes by innate-like T cells is essential for initiation of NASH and fibrosis. Sci Immunol. 2023;8: eadd1599","journal-title":"Sci Immunol"},{"key":"10660_CR71","doi-asserted-by":"publisher","first-page":"e168","DOI":"10.1161\/ATV.0000000000000153","volume":"42","author":"PB Duell","year":"2022","unstructured":"Duell PB, Welty FK, Miller M, Chait A, Hammond G, Ahmad Z, et al. Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2022;42:e168\u2013e185","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10660_CR72","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/S2468-1253(21)00308-3","volume":"6","author":"A Mantovani","year":"2021","unstructured":"Mantovani A, Csermely A, Petracca G, Beatrice G, Corey KE, Simon TG, et al. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2021;6:903\u2013913","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10660_CR73","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1016\/j.cgh.2020.12.022","volume":"19","author":"H Lee","year":"2021","unstructured":"Lee H, Lee YH, Kim SU, Kim HC. Metabolic dysfunction-associated fatty liver disease and incident cardiovascular disease risk: a nationwide cohort study. Clin Gastroenterol Hepatol. 2021;19:2138-2147.e2110","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10660_CR74","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1161\/ATVBAHA.122.318661","volume":"43","author":"KC Sung","year":"2023","unstructured":"Sung KC, Yoo TK, Lee MY, Byrne CD, Zheng MH, Targher G. Comparative associations of nonalcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease with coronary artery calcification: a cross-sectional and longitudinal cohort study. Arterioscler Thromb Vasc Biol. 2023;43:482\u2013491","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10660_CR75","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1136\/gutjnl-2022-328224","volume":"72","author":"A Mantovani","year":"2023","unstructured":"Mantovani A, Csermely A, Tilg H, Byrne CD, Targher G. Comparative effects of non-alcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease on risk of incident cardiovascular events: a meta-analysis of about 13 million individuals. Gut. 2023;72:1433\u20131436","journal-title":"Gut"},{"key":"10660_CR76","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s12072-023-10543-8","volume":"17","author":"XD Zhou","year":"2023","unstructured":"Zhou XD, Targher G, Byrne CD, Somers V, Kim SU, Chahal CAA, et al. An international multidisciplinary consensus statement on MAFLD and the risk of CVD. Hepatol Int. 2023;17:773\u2013791","journal-title":"Hepatol Int"},{"key":"10660_CR77","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41387-022-00182-7","volume":"12","author":"A Ismaiel","year":"2022","unstructured":"Ismaiel A, Spinu M, Socaciu C, Budisan L, Leucuta DC, Popa SL, et al. Metabolic biomarkers related to cardiac dysfunction in metabolic-dysfunction-associated fatty liver disease: a cross-sectional analysis. Nutr Diabetes. 2022;12:4","journal-title":"Nutr Diabetes"},{"key":"10660_CR78","doi-asserted-by":"publisher","first-page":"1007171","DOI":"10.3389\/fendo.2022.1007171","volume":"13","author":"F Lei","year":"2022","unstructured":"Lei F, Qin JJ, Song X, Liu YM, Chen MM, Sun T, et al. The prevalence of MAFLD and its association with atrial fibrillation in a nationwide health check-up population in China. Front Endocrinol (Lausanne). 2022;13:1007171","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10660_CR79","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.957245","volume":"13","author":"R Decoin","year":"2022","unstructured":"Decoin R, Butruille L, Defrancq T, Robert J, Destrait N, Coisne A, et al. High liver fibrosis scores in metabolic dysfunction-associated fatty liver disease patients are associated with adverse atrial remodeling and atrial fibrillation recurrence following catheter ablation. Front Endocrinol (Lausanne). 2022;13: 957245","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10660_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2022.101416","volume":"49","author":"A Mantovani","year":"2023","unstructured":"Mantovani A, Csermely A, Taverna A, Cappelli D, Benfari G, Bonapace S, et al. Association between metabolic dysfunction-associated fatty liver disease and supraventricular and ventricular tachyarrhythmias in patients with type 2 diabetes. Diabetes Metab. 2023;49: 101416","journal-title":"Diabetes Metab"},{"key":"10660_CR81","doi-asserted-by":"publisher","first-page":"1109673","DOI":"10.3389\/fendo.2023.1109673","volume":"14","author":"F Lei","year":"2023","unstructured":"Lei F, Wang XM, Wang C, Huang X, Liu YM, Qin JJ, et al. Metabolic dysfunction-associated fatty liver disease increased the risk of subclinical carotid atherosclerosis in China. Front Endocrinol (Lausanne). 2023;14:1109673","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10660_CR82","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1136\/gutjnl-2020-323082","volume":"71","author":"A Mantovani","year":"2022","unstructured":"Mantovani A, Petracca G, Beatrice G, Csermely A, Lonardo A, Schattenberg JM, et al. Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis. Gut. 2022;71:156\u2013162","journal-title":"Gut"},{"key":"10660_CR83","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.diabet.2019.11.003","volume":"46","author":"DQ Sun","year":"2020","unstructured":"Sun DQ, Ye FZ, Kani HT, Yang JR, Zheng KI, Zhang HY, et al. Higher liver stiffness scores are associated with early kidney dysfunction in patients with histologically proven non-cirrhotic NAFLD. Diabetes Metab. 2020;46:288\u2013295","journal-title":"Diabetes Metab"},{"key":"10660_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2022.101344","volume":"48","author":"CY Jung","year":"2022","unstructured":"Jung CY, Koh HB, Park KH, Joo YS, Kim HW, Ahn SH, et al. Metabolic dysfunction-associated fatty liver disease and risk of incident chronic kidney disease: a nationwide cohort study. Diabetes Metab. 2022;48: 101344","journal-title":"Diabetes Metab"},{"key":"10660_CR85","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s12072-023-10486-0","volume":"17","author":"S Chen","year":"2023","unstructured":"Chen S, Pang J, Huang R, Xue H, Chen X. Association of MAFLD with end-stage kidney disease: a prospective study of 337,783 UK Biobank participants. Hepatol Int. 2023;17:595\u2013605","journal-title":"Hepatol Int"},{"key":"10660_CR86","doi-asserted-by":"publisher","first-page":"386","DOI":"10.21037\/hbsn-22-421","volume":"12","author":"DQ Sun","year":"2023","unstructured":"Sun DQ, Targher G, Byrne CD, Wheeler DC, Wong VW, Fan JG, et al. An international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease. HepatoBiliary Surg Nutr. 2023;12:386","journal-title":"HepatoBiliary Surg Nutr"},{"key":"10660_CR87","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1016\/j.numecd.2021.02.018","volume":"31","author":"DQ Sun","year":"2021","unstructured":"Sun DQ, Wang TY, Zheng KI, Zhang HY, Wang XD, Targher G, et al. The HSD17B13 rs72613567 variant is associated with lower levels of albuminuria in patients with biopsy-proven nonalcoholic fatty liver disease. Nutr Metab Cardiovasc Dis. 2021;31:1822\u20131831","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10660_CR88","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/liv.14251","volume":"40","author":"DQ Sun","year":"2020","unstructured":"Sun DQ, Zheng KI, Xu G, Ma HL, Zhang HY, Pan XY, et al. PNPLA3 rs738409 is associated with renal glomerular and tubular injury in NAFLD patients with persistently normal ALT levels. Liver Int. 2020;40:107\u2013119","journal-title":"Liver Int"},{"key":"10660_CR89","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1161\/CIRCULATIONAHA.118.038868","volume":"139","author":"TA Zelniker","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Furtado RHM, et al. Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus. Circulation. 2019;139:2022\u20132031","journal-title":"Circulation"},{"key":"10660_CR90","doi-asserted-by":"publisher","first-page":"1078149","DOI":"10.3389\/fendo.2023.1078149","volume":"14","author":"Y Liao","year":"2023","unstructured":"Liao Y, Wang L, Liu F, Zhou Y, Lin X, Zhao Z, et al. Emerging trends and hotspots in metabolic dysfunction-associated fatty liver disease (MAFLD) research from 2012 to 2021: a bibliometric analysis. Front Endocrinol (Lausanne). 2023;14:1078149","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10660_CR91","doi-asserted-by":"publisher","first-page":"3970","DOI":"10.3390\/nu15183970","volume":"15","author":"K Yang","year":"2023","unstructured":"Yang K, Song M. New insights into the pathogenesis of metabolic-associated fatty liver disease (MAFLD): gut-liver-heart crosstalk. Nutrients. 2023;15:3970","journal-title":"Nutrients"},{"key":"10660_CR92","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.873048","volume":"12","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Yan S, Sheng S, Qin Q, Chen J, Li W, et al. Comparison of gut microbiota in male MAFLD patients with varying liver stiffness. Front Cell Infect Microbiol. 2022;12: 873048","journal-title":"Front Cell Infect Microbiol"},{"key":"10660_CR93","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202104373","volume":"9","author":"M Zeybel","year":"2022","unstructured":"Zeybel M, Arif M, Li X, Altay O, Yang H, Shi M, et al. Multiomics analysis reveals the impact of microbiota on host metabolism in hepatic steatosis. Adv Sci (Weinh). 2022;9: e2104373","journal-title":"Adv Sci (Weinh)"},{"key":"10660_CR94","doi-asserted-by":"publisher","first-page":"2238959","DOI":"10.1080\/19490976.2023.2238959","volume":"15","author":"J Tan","year":"2023","unstructured":"Tan J, Hu R, Gong J, Fang C, Li Y, Liu M, et al. Protection against metabolic associated fatty liver disease by protocatechuic acid. Gut Microbes. 2023;15:2238959","journal-title":"Gut Microbes"},{"key":"10660_CR95","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1111\/hepr.13795","volume":"52","author":"S Fukunaga","year":"2022","unstructured":"Fukunaga S, Nakano D, Tsutsumi T, Kawaguchi T, Eslam M, Yoshinaga S, et al. Lean\/normal-weight metabolic dysfunction-associated fatty liver disease is a risk factor for reflux esophagitis. Hepatol Res. 2022;52:699\u2013711","journal-title":"Hepatol Res"},{"key":"10660_CR96","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1002\/ueg2.12389","volume":"11","author":"S V\u00e1ncsa","year":"2023","unstructured":"V\u00e1ncsa S, Sipos Z, V\u00e1radi A, Nagy R, Ocskay K, Juh\u00e1sz FM, et al. Metabolic-associated fatty liver disease is associated with acute pancreatitis with more severe course: post hoc analysis of a prospectively collected international registry. United Eur Gastroenterol J. 2023;11:371\u2013382","journal-title":"United Eur Gastroenterol J"},{"key":"10660_CR97","first-page":"37","volume":"2","author":"Y Yilmaz","year":"2021","unstructured":"Yilmaz Y, Yilmaz N, Ates F, Karakaya F, Gokcan H, Kaya E, et al. The prevalence of metabolic-associated fatty liver disease in the Turkish population: a multicenter study. Hepatol Forum. 2021;2:37\u201342","journal-title":"Hepatol Forum"},{"key":"10660_CR98","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.cgh.2022.01.039","volume":"21","author":"JC Rodriguez-Duque","year":"2023","unstructured":"Rodriguez-Duque JC, Calleja JL, Iruzubieta P, Hern\u00e1ndez-Conde M, Rivas-Rivas C, Vera MI, et al. Increased risk of MAFLD and liver fibrosis in inflammatory bowel disease independent of classic metabolic risk factors. Clin Gastroenterol Hepatol. 2023;21:406-414.e407","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10660_CR99","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1007\/s12072-022-10424-6","volume":"17","author":"J Chen","year":"2023","unstructured":"Chen J, Dan L, Tu X, Sun Y, Deng M, Chen X, et al. Metabolic dysfunction-associated fatty liver disease and liver function markers are associated with Crohn\u2019s disease but not Ulcerative Colitis: a prospective cohort study. Hepatol Int. 2023;17:202\u2013214","journal-title":"Hepatol Int"},{"key":"10660_CR100","doi-asserted-by":"publisher","first-page":"2953","DOI":"10.1002\/jcsm.13099","volume":"13","author":"JY Seo","year":"2022","unstructured":"Seo JY, Cho EJ, Kim MJ, Kwak MS, Yang JI, Chung SJ, et al. The relationship between metabolic dysfunction-associated fatty liver disease and low muscle mass in an asymptomatic Korean population. J Cachexia Sarcopenia Muscle. 2022;13:2953\u20132960","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10660_CR101","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1002\/jcsm.12754","volume":"12","author":"HS Chun","year":"2021","unstructured":"Chun HS, Kim MN, Lee JS, Lee HW, Kim BK, Park JY, et al. Risk stratification using sarcopenia status among subjects with metabolic dysfunction-associated fatty liver disease. J Cachexia Sarcopenia Muscle. 2021;12:1168\u20131178","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10660_CR102","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2021.100323","volume":"3","author":"M Nachit","year":"2021","unstructured":"Nachit M, Lanthier N, Rodriguez J, Neyrinck AM, Cani PD, Bindels LB, et al. A dynamic association between myosteatosis and liver stiffness: results from a prospective interventional study in obese patients. JHEP Rep. 2021;3: 100323","journal-title":"JHEP Rep"},{"key":"10660_CR103","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1007\/s10787-021-00842-7","volume":"29","author":"AL Han","year":"2021","unstructured":"Han AL. Association between metabolic associated fatty liver disease and osteoarthritis using data from the Korean national health and nutrition examination survey (KNHANES). Inflammopharmacology. 2021;29:1111\u20131118","journal-title":"Inflammopharmacology"},{"key":"10660_CR104","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1111\/liv.15549","volume":"43","author":"P Yilmaz","year":"2023","unstructured":"Yilmaz P, Alferink LJM, Cremers LGM, Murad SD, Niessen WJ, Ikram MA, et al. Subclinical liver traits are associated with structural and hemodynamic brain imaging markers. Liver Int. 2023;43:1256\u20131268","journal-title":"Liver Int"},{"key":"10660_CR105","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1038\/s41598-022-05228-5","volume":"12","author":"S Nucera","year":"2022","unstructured":"Nucera S, Ruga S, Cardamone A, Coppoletta AR, Guarnieri L, Zito MC, et al. MAFLD progression contributes to altered thalamus metabolism and brain structure. Sci Rep. 2022;12:1207","journal-title":"Sci Rep"},{"key":"10660_CR106","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.atherosclerosis.2017.11.012","volume":"268","author":"L Airaghi","year":"2018","unstructured":"Airaghi L, Rango M, Maira D, Barbieri V, Valenti L, Lombardi R, et al. Subclinical cerebrovascular disease in NAFLD without overt risk factors for atherosclerosis. Atherosclerosis. 2018;268:27\u201331","journal-title":"Atherosclerosis"},{"key":"10660_CR107","doi-asserted-by":"publisher","first-page":"2752","DOI":"10.18632\/oncotarget.22755","volume":"9","author":"J Hu","year":"2018","unstructured":"Hu J, Xu Y, He Z, Zhang H, Lian X, Zhu T, et al. Increased risk of cerebrovascular accident related to non-alcoholic fatty liver disease: a meta-analysis. Oncotarget. 2018;9:2752\u20132760","journal-title":"Oncotarget"},{"key":"10660_CR108","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.jad.2023.02.101","volume":"329","author":"D Kim","year":"2023","unstructured":"Kim D, Dennis BB, Cholankeril G, Ahmed A. Association between depression and metabolic dysfunction-associated fatty liver disease\/significant fibrosis. J Affect Disord. 2023;329:184\u2013191","journal-title":"J Affect Disord"},{"key":"10660_CR109","first-page":"1034","volume":"10","author":"Q Yu","year":"2022","unstructured":"Yu Q, He R, Jiang H, Wu J, Xi Z, He K, et al. Association between metabolic dysfunction-associated fatty liver disease and cognitive impairment. J Clin Transl Hepatol. 2022;10:1034\u20131041","journal-title":"J Clin Transl Hepatol"},{"key":"10660_CR110","doi-asserted-by":"publisher","first-page":"e574","DOI":"10.1212\/WNL.0000000000200853","volume":"99","author":"Y Shang","year":"2022","unstructured":"Shang Y, Widman L, Hagstr\u00f6m H. Nonalcoholic fatty liver disease and risk of dementia: a population-based cohort study. Neurology. 2022;99:e574\u2013e582","journal-title":"Neurology"},{"key":"10660_CR111","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1111\/liv.15244","volume":"42","author":"GA Kim","year":"2022","unstructured":"Kim GA, Oh CH, Kim JW, Jeong SJ, Oh IH, Lee JS, et al. Association between non-alcoholic fatty liver disease and the risk of dementia: a nationwide cohort study. Liver Int. 2022;42:1027\u20131036","journal-title":"Liver Int"},{"key":"10660_CR112","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2021.120117","volume":"434","author":"E Basu","year":"2022","unstructured":"Basu E, Mehta M, Zhang C, Zhao C, Rosenblatt R, Tapper EB, et al. Association of chronic liver disease with cognition and brain volumes in two randomized controlled trial populations. J Neurol Sci. 2022;434: 120117","journal-title":"J Neurol Sci"},{"key":"10660_CR113","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12933-018-0670-7","volume":"17","author":"A Tuttolomondo","year":"2018","unstructured":"Tuttolomondo A, Petta S, Casuccio A, Maida C, Corte VD, Daidone M, et al. Reactive hyperemia index (RHI) and cognitive performance indexes are associated with histologic markers of liver disease in subjects with non-alcoholic fatty liver disease (NAFLD): a case control study. Cardiovasc Diabetol. 2018;17:28","journal-title":"Cardiovasc Diabetol"},{"key":"10660_CR114","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.985109","volume":"14","author":"L Wang","year":"2022","unstructured":"Wang L, Sang B, Zheng Z. Risk of dementia or cognitive impairment in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Front Aging Neurosci. 2022;14: 985109","journal-title":"Front Aging Neurosci"},{"key":"10660_CR115","doi-asserted-by":"publisher","first-page":"e565","DOI":"10.1212\/WNL.0000000000200770","volume":"99","author":"T Xiao","year":"2022","unstructured":"Xiao T, van Kleef LA, Ikram MK, de Knegt RJ, Ikram MA. Association of nonalcoholic fatty liver disease and fibrosis with incident dementia and cognition: the Rotterdam study. Neurology. 2022;99:e565\u2013e573","journal-title":"Neurology"},{"key":"10660_CR116","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.3390\/ijms20112841","volume":"20","author":"A Lonardo","year":"2019","unstructured":"Lonardo A, Mantovani A, Lugari S, Targher G. NAFLD in some common endocrine diseases: prevalence, pathophysiology, and principles of diagnosis and management. Int J Mol Sci. 2019;20:2841","journal-title":"Int J Mol Sci"},{"key":"10660_CR117","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s12020-015-0640-8","volume":"51","author":"G Targher","year":"2016","unstructured":"Targher G, Rossini M, Lonardo A. Evidence that non-alcoholic fatty liver disease and polycystic ovary syndrome are associated by necessity rather than chance: a novel hepato-ovarian axis? Endocrine. 2016;51:211\u2013221","journal-title":"Endocrine"},{"key":"10660_CR118","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1089\/thy.2018.0257","volume":"28","author":"A Mantovani","year":"2018","unstructured":"Mantovani A, Nascimbeni F, Lonardo A, Zoppini G, Bonora E, Mantzoros CS, et al. Association between primary hypothyroidism and nonalcoholic fatty liver disease: a systematic review and meta-analysis. Thyroid. 2018;28:1270\u20131284","journal-title":"Thyroid"},{"key":"10660_CR119","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12916-023-02775-0","volume":"21","author":"D Liu","year":"2023","unstructured":"Liu D, Gao X, Pan XF, Zhou T, Zhu C, Li F, et al. The hepato-ovarian axis: genetic evidence for a causal association between non-alcoholic fatty liver disease and polycystic ovary syndrome. BMC Med. 2023;21:62","journal-title":"BMC Med"},{"key":"10660_CR120","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000025738","volume":"100","author":"X Zeng","year":"2021","unstructured":"Zeng X, Li B, Zou Y. The relationship between non-alcoholic fatty liver disease and hypothyroidism: a systematic review and meta-analysis. Medicine (Baltimore). 2021;100: e25738","journal-title":"Medicine (Baltimore)"},{"key":"10660_CR121","doi-asserted-by":"publisher","first-page":"e434","DOI":"10.1210\/clinem\/dgad016","volume":"108","author":"YL Chen","year":"2023","unstructured":"Chen YL, Tian S, Wu J, Li H, Li S, Xu Z, et al. Impact of thyroid function on the prevalence and mortality of metabolic dysfunction-associated fatty liver disease. J Clin Endocrinol Metab. 2023;108:e434\u2013e443","journal-title":"J Clin Endocrinol Metab"},{"key":"10660_CR122","doi-asserted-by":"publisher","first-page":"1115354","DOI":"10.3389\/fendo.2023.1115354","volume":"14","author":"Y Hu","year":"2023","unstructured":"Hu Y, Zhou F, Lei F, Lin L, Huang X, Sun T, et al. The nonlinear relationship between thyroid function parameters and metabolic dysfunction-associated fatty liver disease. Front Endocrinol (Lausanne). 2023;14:1115354","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10660_CR123","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.dld.2022.11.020","volume":"55","author":"H Fan","year":"2023","unstructured":"Fan H, Li L, Liu Z, Cao L, Chen X, Suo C, et al. The association between thyroid hormones and MAFLD is mediated by obesity and metabolic disorders and varies among MAFLD subtypes. Dig Liver Dis. 2023;55:785\u2013790","journal-title":"Dig Liver Dis"},{"key":"10660_CR124","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.598836","volume":"11","author":"X Zhang","year":"2020","unstructured":"Zhang X, Li R, Chen Y, Dai Y, Chen L, Qin L, et al. The role of thyroid hormones and autoantibodies in metabolic dysfunction associated fatty liver disease: TgAb may be a potential protective factor. Front Endocrinol (Lausanne). 2020;11: 598836","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10660_CR125","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2023-330596","author":"CD Byrne","year":"2024","unstructured":"Byrne CD, Targher G, Tilg H. Thyroid hormone receptor-beta agonists: new MASLD therapies on the horizon. Gut. 2024. https:\/\/doi.org\/10.1136\/gutjnl-2023-330596","journal-title":"Gut"},{"key":"10660_CR126","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.dsx.2020.06.013","volume":"14","author":"P Sharma","year":"2020","unstructured":"Sharma P, Kumar A. Metabolic dysfunction associated fatty liver disease increases risk of severe COVID-19. Diabetes Metab Syndr. 2020;14:825\u2013827","journal-title":"Diabetes Metab Syndr"},{"key":"10660_CR127","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.jhep.2020.09.024","volume":"74","author":"T Marjot","year":"2021","unstructured":"Marjot T, Moon AM, Cook JA, Abd-Elsalam S, Aloman C, Armstrong MJ, et al. Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: an international registry study. J Hepatol. 2021;74:567\u2013577","journal-title":"J Hepatol"},{"key":"10660_CR128","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1111\/liv.14575","volume":"40","author":"YJ Zhou","year":"2020","unstructured":"Zhou YJ, Zheng KI, Wang XB, Sun QF, Pan KH, Wang TY, et al. Metabolic-associated fatty liver disease is associated with severity of COVID-19. Liver Int. 2020;40:2160\u20132163","journal-title":"Liver Int"},{"key":"10660_CR129","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.dld.2020.09.007","volume":"53","author":"L Pan","year":"2021","unstructured":"Pan L, Huang P, Xie X, Xu J, Guo D, Jiang Y. Metabolic associated fatty liver disease increases the severity of COVID-19: a meta-analysis. Dig Liver Dis. 2021;53:153\u2013157","journal-title":"Dig Liver Dis"},{"key":"10660_CR130","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1136\/gutjnl-2020-321611","volume":"69","author":"G Targher","year":"2020","unstructured":"Targher G, Mantovani A, Byrne CD, Wang XB, Yan HD, Sun QF, et al. Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores. Gut. 2020;69:1545\u20131547","journal-title":"Gut"},{"key":"10660_CR131","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.diabet.2019.04.008","volume":"45","author":"A Mantovani","year":"2019","unstructured":"Mantovani A, Lonardo A, Vinco G, Zoppini G, Lippi G, Bonora E, et al. Association between non-alcoholic fatty liver disease and decreased lung function in adults: a systematic review and meta-analysis. Diabetes Metab. 2019;45:536\u2013544","journal-title":"Diabetes Metab"},{"key":"10660_CR132","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s13098-022-00887-w","volume":"14","author":"T Tsutsumi","year":"2022","unstructured":"Tsutsumi T, Nakano D, Kawaguchi M, Hashida R, Yoshinaga S, Takahashi H, et al. MAFLD associated with COPD via systemic inflammation independent of aging and smoking in men. Diabetol Metab Syndr. 2022;14:115","journal-title":"Diabetol Metab Syndr"},{"key":"10660_CR133","doi-asserted-by":"publisher","first-page":"49","DOI":"10.2147\/NSS.S398971","volume":"15","author":"J Huang","year":"2023","unstructured":"Huang J, Chen L, Li X, Chen M, Lin T, Chen G. Association between metabolic-associated fatty liver disease and obstructive sleep apnea: a cross-sectional study. Nat Sci Sleep. 2023;15:49\u201357","journal-title":"Nat Sci Sleep"},{"key":"10660_CR134","doi-asserted-by":"publisher","first-page":"230","DOI":"10.14218\/JCTH.2021.00306","volume":"10","author":"L Miao","year":"2022","unstructured":"Miao L, Yang L, Guo LS, Shi QQ, Zhou TF, Chen Y, et al. Metabolic dysfunction-associated fatty liver disease is associated with greater impairment of lung function than nonalcoholic fatty liver disease. J Clin Transl Hepatol. 2022;10:230\u2013237","journal-title":"J Clin Transl Hepatol"},{"key":"10660_CR135","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1001\/jamadermatol.2022.1609","volume":"158","author":"Z Ruan","year":"2022","unstructured":"Ruan Z, Lu T, Chen Y, Yuan M, Yu H, Liu R, et al. Association between psoriasis and nonalcoholic fatty liver disease among outpatient US adults. JAMA Dermatol. 2022;158:745\u2013753","journal-title":"JAMA Dermatol"},{"key":"10660_CR136","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1007\/s40618-022-01755-0","volume":"45","author":"F Bellinato","year":"2022","unstructured":"Bellinato F, Gisondi P, Mantovani A, Girolomoni G, Targher G. Risk of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis: an updated systematic review and meta-analysis of observational studies. J Endocrinol Invest. 2022;45:1277\u20131288","journal-title":"J Endocrinol Invest"},{"key":"10660_CR137","doi-asserted-by":"publisher","first-page":"1022460","DOI":"10.3389\/fimmu.2022.1022460","volume":"13","author":"C N\u00e4slund-Koch","year":"2022","unstructured":"N\u00e4slund-Koch C, Bojesen SE, Gluud LL, Skov L, Vedel-Krogh S. Non-alcoholic fatty liver disease is not a causal risk factor for psoriasis: a Mendelian randomization study of 108,835 individuals. Front Immunol. 2022;13:1022460","journal-title":"Front Immunol"},{"key":"10660_CR138","first-page":"517","volume":"19","author":"J Heitmann","year":"2021","unstructured":"Heitmann J, Frings VG, Geier A, Goebeler M, Kerstan A. Non-alcoholic fatty liver disease and psoriasis - is there a shared proinflammatory network? J Dtsch Dermatol Ges. 2021;19:517\u2013528","journal-title":"J Dtsch Dermatol Ges"},{"key":"10660_CR139","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.959691","volume":"13","author":"SY Gau","year":"2022","unstructured":"Gau SY, Hsiao YP, Liao WC, Ma KS, Wu MC. Risk of liver dysfunction and non-alcoholic fatty liver diseases in people with hidradenitis suppurativa: a systematic review and meta-analysis of real-world evidences. Front Immunol. 2022;13: 959691","journal-title":"Front Immunol"},{"key":"10660_CR140","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3597","volume":"100","author":"I Gonz\u00e1lez-Villanueva","year":"2020","unstructured":"Gonz\u00e1lez-Villanueva I, DeGracia C, Planells M, Poveda I, \u00c1lvarez P, Schneller-Pavalescu L, et al. Hidradenitis suppurativa is associated with non-alcoholic fatty liver disease: a cross-sectional study. Acta Derm Venereol. 2020;100: a00239","journal-title":"Acta Derm Venereol"},{"key":"10660_CR141","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1111\/jdv.15764","volume":"33","author":"C Dur\u00e1n-Vian","year":"2019","unstructured":"Dur\u00e1n-Vian C, Arias-Loste MT, Hern\u00e1ndez JL, Fern\u00e1ndez V, Gonz\u00e1lez M, Iruzubieta P, et al. High prevalence of non-alcoholic fatty liver disease among hidradenitis suppurativa patients independent of classic metabolic risk factors. J Eur Acad Dermatol Venereol. 2019;33:2131\u20132136","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10660_CR142","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s12072-022-10458-w","volume":"17","author":"SM Lee","year":"2023","unstructured":"Lee SM, Cho GJ, Wi WY, Norwitz ER, Koo BK, Lee J, et al. Metabolic dysfunction-associated fatty liver disease as a risk factor for adverse outcomes in subsequent pregnancy: a nationwide cohort study. Hepatol Int. 2023;17:367\u2013376","journal-title":"Hepatol Int"},{"key":"10660_CR143","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1016\/j.cgh.2021.11.007","volume":"20","author":"SM Lee","year":"2022","unstructured":"Lee SM, Jung YM, Choi ES, Kwak SH, Koo JN, Oh IH, et al. Metabolic dysfunction-associated fatty liver disease and subsequent development of adverse pregnancy outcomes. Clin Gastroenterol Hepatol. 2022;20:2542-2550.e2548","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10660_CR144","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2022.110038","volume":"191","author":"TY Chai","year":"2022","unstructured":"Chai TY, Deng D, Byth K, George J, Pasupathy D, Cheung NW. The prevalence of metabolic dysfunction-associated fatty liver disease and its association on adverse pregnancy outcomes in women with gestational diabetes mellitus. Diabetes Res Clin Pract. 2022;191: 110038","journal-title":"Diabetes Res Clin Pract"},{"key":"10660_CR145","first-page":"31","volume":"31","author":"S Li","year":"2022","unstructured":"Li S, Xu Z, Li H, Tang J, Liang XY, Tian S, et al. An observational and cross-sectional study of the prevalence of breast lesions and metabolic dysfunction-associated fatty liver disease and their relationship in China. J Gastrointestin Liver Dis. 2022;31:31\u201339","journal-title":"J Gastrointestin Liver Dis"},{"key":"10660_CR146","doi-asserted-by":"publisher","first-page":"557","DOI":"10.3390\/jcm12020557","volume":"12","author":"A Giannouli","year":"2023","unstructured":"Giannouli A, Efthymiou V, Konidari M, Mani I, Aravantinos L, Dourakis SP, et al. The burden of non-alcoholic fatty liver disease in adolescents with polycystic ovary syndrome: a case-control study. J Clin Med. 2023;12:557","journal-title":"J Clin Med"},{"key":"10660_CR147","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/s12902-023-01456-6","volume":"23","author":"X Hong","year":"2023","unstructured":"Hong X, Guo Z, Yu Q. Hepatic steatosis in women with polycystic ovary syndrome. BMC Endocr Disord. 2023;23:207","journal-title":"BMC Endocr Disord"},{"key":"10660_CR148","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s12874-017-0453-y","volume":"17","author":"CM Faggion Jr","year":"2017","unstructured":"Faggion CM Jr, Bakas NP, Wasiak J. A survey of prevalence of narrative and systematic reviews in five major medical journals. BMC Med Res Methodol. 2017;17:176","journal-title":"BMC Med Res Methodol"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-024-10660-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-024-10660-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-024-10660-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T14:06:18Z","timestamp":1727964378000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-024-10660-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,9]]},"references-count":148,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10660"],"URL":"https:\/\/doi.org\/10.1007\/s12072-024-10660-y","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,9]]},"assertion":[{"value":"22 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors (Jing Zhao, Lu Liu, Ying-Ying Cao, Xin Gao, Giovanni Targher, Christopher D. Byrne, Dan-Qin Sun, Ming-Hua Zheng) have confirmed that there are no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availiability"}}]}}